Navigation Links
Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones

FREMONT, Calif., March 4 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRMLD), a molecular diagnostics company, today highlighted recent accomplishments across its diagnostic test programs and provided a preview of key business milestones it plans to achieve over the course of 2008. The Company also released financial results for the fourth quarter and year ended December 31, 2007.

"In 2007, Vermillion made significant clinical and commercial advancements in our diagnostic programs for peripheral artery disease (PAD), ovarian cancer and thrombotic thrombocytopenic purpura (TTP)," said Gail Page, President and CEO of Vermillion. "Our vision is to provide novel diagnostic tools to physicians in an effort to improve patient diagnosis and care. We continue to build awareness of the potential value proposition of our tests. Our primary focus will be on commercialization pathways in 2008."

Recent Accomplishments

Throughout the fourth quarter of 2007 and into the first quarter of 2008, Vermillion has advanced its PAD and ovarian cancer diagnostic programs, as well as accomplished numerous achievements at the corporate level:

PAD Diagnostic Test Progress

-- Completed a 540-patient clinical study evaluating the ability of

Vermillion's multi-marker panel to stratify individuals into high and

low risk groups for PAD. These results have been accepted for

publication in a peer-reviewed clinical journal and are expected to be

published in the first half of this year.

-- Entered into an exclusive license agreement with Stanford University to

develop and commercialize a biomarker panel used to assess the risk of

PAD. Under the terms of the agreeme

SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
2. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
3. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
4. Vermillion to Webcast Presentation at the Acumen BioFin 9th Annual Healthcare Conference, November 5-7, New York
5. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
6. Vermillion Receives NASDAQ Notice of Non-Compliance
7. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
8. Vermillion Announces Effectiveness of Reverse Stock Split
9. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
10. Access Highlighted in Recent BusinessWeek Article
11. ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
Post Your Comments:
(Date:8/20/2014)... The 6th Annual Arrowhead Personalized ... October 29-30 in San Francisco, CA. This year’s conference ... researchers and clinicians focused on addressing and solving the ... the twelve years since the sequencing of the human ... with pharmacogenetic information in the label and molecular diagnostics ...
(Date:8/20/2014)... Calif. , Aug. 20, 2014 /PRNewswire-iReach/ -- ... the transformative collaboration between the school,s bioengineering department ... part of the Intel® Software Academic Program, UCSD,s ... sciences and the human body.  ... The study exhibits the work of Dr. ...
(Date:8/20/2014)... 2014 WriteResult®, a leading provider of ... has expanded its myPROpad™ ePRO tablet with the addition ... of the most widely used and well-respected Patient Reported ... The EQ-5D is used during clinical trials and in ... can be used to demonstrate Health-Related Quality of Life ...
(Date:8/19/2014)... 2014 One of the major ... an inadequate vascular supply. Nutrient and gas transport ... is critical for successful regeneration and integration into ... deficiencies in vascularization and promote angiogenesis in a ... scaffold design and architecture, and enhancing scaffolds with ...
Breaking Biology Technology:6th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2EQ-5D™ Assessment Now Available for iPad 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2
... (NYSE Amex: CUR ) announced that the ongoing ... in amyotrophic lateral sclerosis (ALS or Lou Gehrig,s disease) was ... (Logo: The trial ... injections. About Neuralstem ...
... N.J., Nov. 13, 2011 Pharmasset, Inc. (Nasdaq: ... Capital Markets 8th Annual Healthcare Conference to be held November ... Schaefer Price, Pharmasset,s President and Chief Executive Officer, will provide ... 3:00 PM (ET). To access a simultaneous webcast ...
... Discharge 1-2-3 of Schaumburg, IL has been ... Innovation Awards for their Discharge 1-2-3 Composer™. The ... Theater on Tuesday, November 8, with more than 1400 people ... the Chicago region,s foremost recognition of the most innovative new ...
Cached Biology Technology:Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta 2Pharmasset to Present at the Lazard Capital Markets Healthcare Conference 2Pharmasset to Present at the Lazard Capital Markets Healthcare Conference 3Callibra, Inc. dba Discharge 1-2-3 is Named Winner of 2011 Chicago Innovation Award 2Callibra, Inc. dba Discharge 1-2-3 is Named Winner of 2011 Chicago Innovation Award 3
(Date:8/20/2014)... State University, the Wellcome Trust Sanger Institute and the ... Mycobacterium pinnipedii from skeletons found in Peru ... is a relative of the TB bacterium that affects ... These researchers assume that seals carried the pathogens from ... lions was unexpected" comments Sebastien Gagneux, from the Swiss ...
(Date:8/20/2014)... Research UK scientists have discovered that acral melanomas the ... Marley,s death are genetically distinct from other more common ... external) published in the journal Pigment Cell & Melanoma ... of the hands, soles of the feet, nail-beds and other ... of melanoma, it,s not caused by UV damage from the ...
(Date:8/20/2014)... could one day be made out of cocoa, rice ... reporting. The novel process they developed and their results, ... and plastic waste problems, appear in the ACS journal ... and colleagues at the Italian Institute of Technology point ... its production reached 288 million tons worldwide, but its ...
Breaking Biology News(10 mins):Scientists learn more about rare skin cancer that killed Bob Marley 2
... Leuven, Belgium - When a blood vessel clogs up, a ... die. However, working with mice, VIB scientists connected to the ... with severe hypoxia from dying. The muscles seem to adapt ... force that animals also use when hibernating, but that has ...
... critical difference between flu viruses that infect birds and humans, ... avian flu strains and aid in the development of vaccines ... a virus,s ability to infect humans depends on whether it ... surface of human respiratory cells. Now that we know ...
... in marine biomedical laboratories at Scripps Institution of Oceanography ... information about the fundamental biological processes inside a marine ... to treat cancer in humans. The finding could lead ... human diseases. A research team led by Bradley ...
Cached Biology News:Medical breakthrough for organ transplants and cardiovascular diseases by Flemish researchers 2MIT finds key to avian flu in humans 2MIT finds key to avian flu in humans 3Researchers uncover key trigger for potent cancer-fighting marine product 2
... Extraction Software reads and processes ... prepare microarray data for analysis. ... one 1-year license for ... accounts ,one CD-ROM containing Feature ...
... Last innovation from Magnetofection technology, ... delivery system available. Simple, rapid and ... compatible and non toxic. Specifically designed ... gene silencing at very low doses ...
... handling system from Molecular Devices provides precise ... instrument. The system handles a variety of ... 384- and 1536-welland is the first to ... been optimized to dispense from four different ...
... Radiolabeled Ligands\n\nReceptor-related research has long been enabled ... ligands selected to keep pace with new ... products and services for receptor research and ... If you do not find exactly what ...
Biology Products: